Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Blueprint Medicines Co. (NASDAQ:BPMC) has been assigned an average rating of “Moderate Buy” from the twenty analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $123.56.

A number of equities research analysts recently commented on BPMC shares. Wedbush reaffirmed an “outperform” rating and set a $124.00 price objective (down from $135.00) on shares of Blueprint Medicines in a research note on Monday, January 13th. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Piper Sandler increased their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday. Stephens restated an “overweight” rating and set a $140.00 price objective on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Monday, January 13th.

Insider Transactions at Blueprint Medicines

In related news, CEO Kate Haviland sold 1,446 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey W. Albers sold 15,161 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the transaction, the director now directly owns 152,396 shares in the company, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 49,851 shares of company stock valued at $4,984,696 over the last 90 days. 4.21% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Quarry LP bought a new position in Blueprint Medicines during the third quarter worth about $32,000. R Squared Ltd acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $51,000. Covestor Ltd increased its holdings in shares of Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 403 shares during the last quarter. Van ECK Associates Corp raised its stake in Blueprint Medicines by 48.2% in the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 363 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Blueprint Medicines during the 3rd quarter valued at $108,000.

Blueprint Medicines Stock Down 0.1 %

Shares of NASDAQ BPMC opened at $114.32 on Thursday. Blueprint Medicines has a 1 year low of $72.24 and a 1 year high of $121.90. The firm’s 50-day moving average is $97.07 and its 200-day moving average is $95.27. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $7.26 billion, a PE ratio of -54.18 and a beta of 0.61.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The firm had revenue of $128.20 million for the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business’s revenue for the quarter was up 126.5% on a year-over-year basis. During the same period last year, the firm earned ($2.20) earnings per share. Equities analysts expect that Blueprint Medicines will post -3.67 EPS for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.